Industry & Policy News

[Fierce Biotech] As well as the $47 million upfront payment, Orionis will be eligible for over $2 billion in milestone payments on top of royalties. Molecular glues are small molecules used to stabilize the interaction between two proteins that don’t typically interact.

[Menarini] The Menarini Group and Therapeutics Inc. announced today that the European Commission has approved ORSERDU®. With this approval, ORSERDU becomes the first and only therapy specifically indicated for the treatment of estrogen receptor (ER)+, HER2- tumors that harbor ESR1 mutations.

[Arc Institute] Arc Institute announced the selection of its new fully funded Core Investigator and first Science Fellow, along with its first Innovation Investigators and Ignite Award Recipients.

[Genprex, Inc.] Genprex Inc. was granted FDA orphan drug designation for its REQORSA(R) immunogene therapy in development for the treatment of SCLC.

[Fierce Biotech] The case centers on a webpage for Roche’s Rozlytrek, a drug used to treat ROS1-positive non-small cell lung cancer and NTRK fusion-positive solid tumors. After viewing Roche’s U.K. resources website, an anonymous person complained to the Prescription Medicines Code of Practice Authority (PMCPA) that the content was misleading and not fair or balanced because it omitted critical information.

[MD Anderson Cancer Center] Regular and intense aerobic exercise may reduce the risk of colorectal cancer in patients with Lynch Syndrome by improving the immune system's ability to detect and remove potentially harmful cells, according to researchers at The University of Texas MD Anderson Cancer Center.